Spiegel R. — Psychopharmacology: an introduction :: Электронная библиотека попечительского совета мехмата МГУ

Главная Ex Libris Книги Журналы Статьи Серии Каталог Wanted Загрузка ХудЛит Справка Поиск по индексам Поиск Форум

Авторизация

Поиск по указателям

Spiegel R. — Psychopharmacology: an introduction

Обсудите книгу на научном форуме

Нашли опечатку?
Выделите ее мышкой и нажмите Ctrl+Enter

Название: Psychopharmacology: an introduction

Автор: Spiegel R.

Аннотация:

Describes the latest advances in psychopharmacology - one of the most rapidly developing fields in modern science. This latest edition has been updated to cover new developments in drug therapy and research including newly introduced antipsychotics, antidepressants and antidementia drugs. Sections on the treatment of depression and dementia have been revised to include new developments in treatment strategies. It will be welcomed for its essentially clinical and psychological approach to modern pharmaceuticals, their therapeutic uses and limitations, adverse reactions and future directions for research.

Язык:

Рубрика: Медицина и здравоохранение/

Статус предметного указателя: Готов указатель с номерами страниц

ed2k: ed2k stats

Издание: fouth edition

Год издания: 2003

Количество страниц: 400

Добавлена в каталог: 11.12.2005

Операции: Положить на полку | Скопировать ссылку для форума | Скопировать ID

Предметный указатель

Ritalin $\textregistered$       25
Ritanserin      52
Rivastigmine      26
Rivastigmine as antidementia      53—54 96 126
Rivastigmine, cholinesterase inhibition by      255—256
RNA      139
Rohypnol $\textregistered$       19
Rolipmm, $^{11}C$ -labelled      226
RS 86      54 88—89
S-adenosyl-methionine      133
Saletu, B.      76 82 85 87
Scales, general      204—205
Schildkraut, J.      119
Schizoaffective disorder      15
Schizophrenia      1 6 37 148 227 313 315
Schizophrenia and antipsychotic drugs      1 230—233
Schizophrenia and decisional capacity      151
Schizophrenia and ego disturbances      4
Schizophrenia and placebo      152 169
Schizophrenia and suicide      181
Schizophrenia, biasing trials      177
Schizophrenia, catatonic      264
Schizophrenia, clinical manifestations of      228
Schizophrenia, cognitive impairment in      228—230
Schizophrenia, dopamine hypothesis of      113—116 126 163—164 320
Schizophrenia, dopamine hypothesis of, further developments      116—117
Schizophrenia, drug therapy and psychotherapy      269—274
Schizophrenia, ganglion function and      215
Schizophrenia, glutamatergic hypothesis      117—118
Schizophrenia, models of      131—132
Schizophrenia, negative symptoms      264
Schizophrenia, paranoid-hallucinatory      264
Schizophrenia, pharmacoeconomics of      305
Schizophrenia, prodromal      268
Schizophrenia, self-reporting      306
Schizophrenia, serotonin hypothesis of      112—113
Schizophrenia, simplex      264
Schizophrenia, subjective experiences of      306
Schizophrenia, treatment with antipsychotics      18 26 40—41 50—52 55 263—274
Schizophrenia, two-factor theory of      116
Schizophrenia, two-type theory of      116
Schizophrenic psychoses      29 180 319—320
Schneider, P.J.      32—34
Schneider, P.J., classification of psychotropic agents by      32
Schneider, P.J., Materia Medica of      32—33
Schou, M.      43
SCID      see Structured Clinical Interview for DSM-IV Axis I Disorders
SCL-90-R      see Symptoms Checklist-Revised
Scopolamine      35—36 70 94 189
Scopolamine, challenge      188
Scopolamine, model      97
Second messenger      104 106
Sedalande $\textregistered$       5
Sedation      14 17 20 23 90 185 293
Sedation, mild      76
Sedatives      6—8 10 18—19 28 36 38—39 41 44 90 234 242
Sedatives, abuse      291
Sedatives, risks of      44
Seizure      14 17
Selective noradrenaline reuptake inhibitors (SNRIs)      11 13—14 55
Selective noradrenaline reuptake inhibitors (SNRIs) and anxiety disorder      26 245 292—293 296
Selective noradrenaline reuptake inhibitors (SNRIs) and cognitive function      238—239
Selective noradrenaline reuptake inhibitors (SNRIs) and panic disorder      292—293
Selective noradrenaline reuptake inhibitors (SNRIs), defined      126
Selective noradrenaline reuptake inhibitors (SNRIs), multiple action of      127
Selective serotonin reuptake inhibitor (SSRI)      11 13—15 50 52—53 55 167
Selective serotonin reuptake inhibitor (SSRI) and anxiety disorder      26 128 245 292—293 296
Selective serotonin reuptake inhibitor (SSRI) and cognitive function      238—239
Selective serotonin reuptake inhibitor (SSRI) and depression      120 122 276—277
Selective serotonin reuptake inhibitor (SSRI) and panic disorder      187—188 292—293
Selective serotonin reuptake inhibitor (SSRI) and sexual dysfunction      194
Selective serotonin reuptake inhibitor (SSRI), defined      126
Selective serotonin reuptake inhibitor (SSRI), discovery/introduction      46
Selective serotonin reuptake inhibitor (SSRI), effects, behavioral      81
Selective serotonin reuptake inhibitor (SSRI), effects, metabolic      217
Selective serotonin reuptake inhibitor (SSRI), multiple action of      127
Selective serotonin reuptake inhibitor (SSRI), stress model of      133
Selective serotonin reuptake inhibitor (SSRI), time lag of      124
Senile dementia      26
Serax $\textregistered$       19
Serentil $\textregistered$       5
Seresta $\textregistered$       19
Seropram $\textregistered$       11
Seroquel $\textregistered$       5
Serotonic syndrome      14
Serotonin (5-HT)      53 110—111 113 119 126—127
Serotonin (5-HT), 5-HT2 antagonist      52
Serotonin (5-HT), precursors      119
Serotonin (5-HT), receptors      52
Serotonin (5-HT), reuptake blocked      53
Serotonin norepinephrine reuptake inhibitor (SNRI)      36
Seroxat $\textregistered$       11
Sertindole      163 177
Sertraline      11
Sertraline and CFF      81
Sertraline and depression      276
Sertraline and OCD      23
Sertraline and panic disorder      23
Sertraline and PTSD      23
Sertraline and social phobia      294
Sertraline, action spectra of      12
Sertraline, side effects of      14
Sertraline, studies/trials of      172 177 191 238—240
Sertuerner, F.      28
Serzone $\textregistered$       11
Sevofturane      218
Sexual dysfunction      7 14 194 276
SF-36      205
SF-36, instrument      307
Sheehan Disability Scale      204
Sherrington, C.      221
Shock      37
Shock, cardiazole-induced      36
Shock, description of      37
Shock, exogenous substances, and      37
Shock, therapies      36 50
SI-PTSD      see Structured Interview for PTSD
Side effects      2 7 51 261
Side effects of mood stabilizers      17
Side effects, multiple interactions, and      127
Sigma ligands      123
Sinequan $\textregistered$       11
Single-case design      178
Single-photon-emission computed tomography (SPECT)      162 187 211 324
Sinus node dysfunction      17
Sleep attacks      24
Sleep, deprivation      24 323
Sleep, disorders      20 26 36 178
Sleep, paralysis      24—25
Sleep, polygrams      71 73—74 77 79 80—81 83 85 87—89 94—96
Sleep, polygrams, advantages of      72
Sleep, psychotrophic substances and      73—74
Sleep, research      71
Sleep, therapy      38—39 46
Snakeroot      29
SNRI      see serotonin norepinephrine reuptake inhibitor
Social interaction test      136
Social phobia      19 23 169 242 291—292 294 296
Social skills therapy, studies in depression      288—289
Social skills training      273
Societe Medico-Psychologique      39
Sodium lactate infusion challenge      187—188
Sokoloff, L.      215
Solubility      156
Somatic      13
Somatostatin      110
Somatotherapies, psychiatric, discovery of      46
Somnite $\textregistered$       19
Somnolence      14
Sonata $\textregistered$       19

Sordinol $\textregistered$       5
Spasms of tongue      8
Spasms, pharyngeal      8
Spasms, visual      8
SPECT      see single-photon-emission computed tomography
Speech blockage      236
Speech disturbances      45
Speed (drug)      24
Spielberger State-Trait Anxiety Inventory (SSTAI)      200
SSRI      see selective serotonin reuptake inhibitor
St John's won      133—134
Staehelin, J.E.      40
State-dependent learning      250
Statins      259
Stelazine $\textregistered$       5
Stembach, L.      44—15 48
Sterility, transient, caused by antipsychotics      7
Stevens — Johnson syndrome      17
Stiffness      267
Stimulants      2 185
Stimulants, catecholaminergic      87
Stimulus-correlated potentials      75
Stress disorder, acute      19 291—292
Stress-induced hyperthermia test      135—136
Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)      197 201
Structured Interview for PTSD (SI-PTSD)      201
Study designs      164—183
Study designs, alternatives to placebo      173—174
Study designs, bias minimization methodology      179—180
Study designs, case-control studies      182
Study designs, comparative      174—178
Study designs, longitudinal      180—182
Study designs, need for control of      164—165
Study designs, parallel-group designs      165—166
Study designs, placebo-controlled designs      166—173
Study designs, within patient      178—179
Subjects, healthy, definition of      58
Subjects, healthy, effects of psychotropic medication on      57—97
Subjects, healthy, findings in drug experiments on      76—89
Subjects, healthy, findings in drug experiments on, antidepressant drugs      80
Subjects, healthy, findings in drug experiments on, antipsychotic drugs      77
Subjects, healthy, variability of      159
Substance P      110
Substance use scales      204
Sugars, in functional imaging      209
suicide      277
Suicide in depression      15 25
Suicide, analysis of      183
Suicide, attempted      13 18
Suicide, risk of      152 155 179 181 194
Sulfonal      35—36
Sulpiride      5
Sulpiride, effects of      77—79 89
Surmontil $\textregistered$       11
Surrogate endpoint      163
Sweating      7—8 13—14 18 21 76 124 267 292
Symptom Checklist, Revised 90-Item      63
Symptoms Checklist-Revised (SCL-90-R)      204
Symptoms, extrapyramidal (EPS)      52
Symptoms, extrapyramidal (EPS), motor      7
Symptoms, mental      13
Synapses      102—106 324
Synapses, chemical      103—104
Synapses, chemical, cross-talk between neurons      103—106
Synapses, chemical, polarization      104
Synapses, defined      105
Synapses, electrical      102
Synapses, electrical, cross-talk between neurons      103
Synapses, excitary      103
Synapses, inhibitory      103
Synaptic cleft      105
T wave changes      17
tablets      6
Tachycardia      25 293
Tachyphylaxis      24
Tacrine      26 46 54 89
Tail suspension test      132
Talairach atlas      Plate 6.1
Taractan $\textregistered$       5
Target product profile (TPP)      147
Tea      59—60
Tea, performance improved by      60—61
Technetium $(^{99}Tc)$ chelates, in functional imaging      208—209
Tegretol $\textregistered$       16 17
Temazepam      19
Tenox $\textregistered$       19
Tension      2 17 20
Tension, affective      3
Theory-oriented issues      96—97
Therapy, continuation      277
Therapy, possibilities of combinations      288
Therapy, preferred forms for anxiety syndromes      296
Theriak      28
Thioridazine      5 114 163 230 263
Thioridazine, action spectra of      12
Thiotbixine      5
Thorazine $\textregistered$       5
Thorn apple      34
Thymeretics      1 12
Thymoleptics      1 9 12 41
Thyroid      17
Tiagabine      16 241
Tics      25
Tigmotaxis      130
Tindal $\textregistered$       5
Tiredness      13 20 23 76
TMS      see transcranial magnetic stimulation
Tobacco      161
Tofranil $\textregistered$       11
Tolerability      183—186
Tolerance      293
Tolvon $\textregistered$       11
Tongue, dyskinetic movements of      7
TOP-S      see Treatment Outcome PTSD Scale
Topamax      16
Topiramate      16 241
Tower of London test      70
Toxicology studies      183—184
TPP      see target product profile
Trade names      5
Trail Making B      229
Tranquillizers      1—2 43—15 47 291—292
Transcranial magnetic stimulation (TMS)      123
Transient state of unrest      296
Tranxene $\textregistered$       19
Tranylcypromine      41 12 279
Trazodone      11 13 15 23 236
Trazodone, action spectra of      12
Trazodone, effects of      81—82
Trazodone, side effects      14
Treatment Outcome PTSD Scale (TOP-8)      201
Treatment, chronic      278
Treatment, costs, direct      304
Treatment, costs, indirect      305
Treatment, costs, of infomial caregiving      304—305
Treatment, long-term, dosage of antipsychotics during      265—266
Treatment, long-term, duration and compliance      266—267
Treatment, long-term, studies of      270—274
Treatment, recommended      295—296
Treatment, resistance      15 194 264
Treatment, studies      174
Trembling      292
Tremor      8 14 17 21 124 267 293
Trials, blank      60
Trials, organization of      61
Trials, tachistoscopic      66—67
Triazolam      19
Tricyclic antidepressants      13 53 83 133 162
Trifluoperazine      5 263 272
Trifluoperazine, effects of      77—78

1 2 3 4 5 6 7 8

О проекте